scispace - formally typeset
Ş

Şevki Adem

Researcher at Çankırı Karatekin University

Publications -  54
Citations -  796

Şevki Adem is an academic researcher from Çankırı Karatekin University. The author has contributed to research in topics: Enzyme & Chemistry. The author has an hindex of 11, co-authored 40 publications receiving 391 citations.

Papers
More filters
Posted ContentDOI

Identification of Potent COVID-19 Main Protease (Mpro) Inhibitors from Natural Polyphenols: An in Silico Strategy Unveils a Hope against CORONA

TL;DR: Wang et al. as mentioned in this paper evaluated the efficacy of medicinal plant-based bioactive compounds against SARS-CoV-2 Mpro by molecular docking study using Molegro Virtual Docker 7 to analyze the inhibition probability of these compounds against COVID-19.
Journal ArticleDOI

Caffeic acid derivatives (CAFDs) as inhibitors of SARS-CoV-2: CAFDs-based functional foods as a potential alternative approach to combat COVID-19.

TL;DR: This study will hopefully pave a way for development of phytonutrients-based antiviral therapeutic for treatment or prevention of COVID-19 and further studies are recommended to evaluate the antiviral effects of these phytochemicals against SARS-CoV-2 in in vitro and in vivo models.
Journal ArticleDOI

Synthesis, spectroscopic characterizations, enzyme inhibition, molecular docking study and DFT calculations of new Schiff bases of sulfa drugs

TL;DR: In this paper, new Schiff bases were synthesized (Z)-4-((4-(diethylamino)benzylidene)amino)-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide (L1) and (Z]-4-(4-(dimethylamino), amino amino) amino)-n-(5-methylisoxosol-3-yl), N-(5 -methylisocazol)-3 -yl)benedienesulfoneamide (
Journal ArticleDOI

Ginkgetin: A natural biflavone with versatile pharmacological activities.

TL;DR: Ginkgetin shows substantial preventive or therapeutic effects in in vivo models of many diseases including atherosclerosis, cancer, neurodegenerative, hepatic, influenza, and inflammatory diseases.
Journal ArticleDOI

Hispolon: A natural polyphenol and emerging cancer killer by multiple cellular signaling pathways.

TL;DR: It is proposed that hispolon provides a novel opportunity for pharmacological applications and its styrylpyrone carbon skeleton might serve as an attractive scaffold for drug development, and future researchers are recommended to assess bioavailability, toxicological limits, pharmacokinetic and pharmacodynamic profiles of hisPolon, in order to establish its potential as a potent multi-targeted drug in the near future.